AbbVie Acquires Pharmacyclics for $21 Billion to Secure Imbruvica Cancer Drug Rights
Key Insights
AbbVie (search) outbid Johnson & Johnson and Novartis to acquire Pharmacyclics (search) for $21 billion, paying a 13% premium over the biotech's closing price.
The acquisition gives AbbVie (search) rights to Imbruvica (ibrutinib), a chronic lymphocytic leukemia treatment expected to exceed $1 billion in sales this year.
The deal aims to diversify AbbVie (search)'s pipeline as its blockbuster drug Humira faces patent expiration and declining sales in coming years.
AbbVie (search) announced Thursday it will acquire Pharmacyclics (search) for $21 billion in a cash and stock deal, beating out pharmaceutical giants Johnson & Johnson and Novartis in a competitive bidding process. The acquisition represents a 13% premium over Pharmacyclics' Wednesday closing price at $261.25 per share, significantly higher than the $17-18 billion range analysts had expected from competing bidders.
Strategic Pipeline Diversification
The acquisition centers on securing rights to Imbruvica (ibrutinib), Pharmacyclics (search)' chronic lymphocytic leukemia treatment that represents a critical addition to AbbVie (search)'s oncology pipeline. Imbruvica is expected to exceed $1 billion in sales this year and reach $5.8 billion globally by 2020, according to projections.
The deal addresses AbbVie (search)'s urgent need to diversify its revenue streams as Humira, currently the world's top-selling drug, faces patent expiration and declining sales over the next several years. CEO Richard A. Gonzalez described the acquisition as "a strategically compelling opportunity" that would add "enormous value to AbbVie" through Pharmacyclics (search)' "talented and innovative team."
Financial Structure and Market Response
AbbVie (search) will pay $152.25 in cash and $109 per share in stock, with the number of shares issued dependent on AbbVie's stock price at closing. The company plans to buy back at least 50% of the shares it issues to fund the takeover. CFO Bill Chase projected 60 cents of earnings per share accretion by 2019, though he also forecast a 20-cent EPS hit in 2015.
Despite the strategic rationale, investor reaction was mixed. AbbVie (search) shares declined Thursday as analysts questioned the high valuation. Citigroup analyst Andrew S. Baum called the "strategy defensible, valuation less so," recommending selling AbbVie shares with a price target as low as $48 per share. Baum noted that while Imbruvica could account for 30-35% of Pharmacyclics (search)' price tag, AbbVie would need to find as much as $5 billion in revenue outside of the drug to justify the acquisition.
Acquisition Context and Industry Implications
The deal represents a major victory for AbbVie (search) CEO Richard A. Gonzalez following the company's failed $54 billion takeover attempt of Ireland-based Shire Pharmaceuticals, which was blocked by U.S. government restrictions on tax inversion transactions.
For Pharmacyclics (search) Chairman and CEO Robert Duggan, the acquisition proved highly lucrative. Duggan's net worth reached $3.5 billion as Pharmacyclics shares surged over 10% Thursday, with his holdings gaining $1.2 billion in value since February 13.
The transaction occurs amid a broader consolidation wave in the pharmaceutical industry, with healthcare M&A volumes rising nearly 40% in 2014 to $412 billion. However, some analysts warn that the aggressive bidding and high valuations may signal industry overreach, particularly as mid-tier drugmakers use M&A to compete with global pharmaceutical giants.
UBS analyst Mark Goodman offered a more optimistic view, suggesting that if "Imbruvica does in fact reach consensus numbers, then this will prove to be a good deal for AbbVie (search)," drawing parallels to Gilead's successful acquisition of Pharmasset, which initially appeared expensive but ultimately proved valuable.